AstraZeneca PLC (LON:AZN)

London flag London · Delayed Price · Currency is GBP · Price in GBX
12,806
+26 (0.20%)
Oct 8, 2025, 6:36 PM BST
0.20%
Market Cap198.18B
Revenue (ttm)41.24B
Net Income (ttm)6.05B
Shares Out1.55B
EPS (ttm)3.87
PE Ratio32.98
Forward PE17.56
Dividend2.38 (1.86%)
Ex-Dividend DateAug 7, 2025
Volume2,924,907
Average Volume2,371,543
Open12,806
Previous Close12,780
Day's Range12,774 - 12,972
52-Week Range9,574 - 12,972
Beta0.16
RSI72.70
Earnings DateNov 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]

Sector Healthcare
Founded 1992
Employees 94,300
Stock Exchange London Stock Exchange
Ticker Symbol AZN
Full Company Profile

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD Financial Statements

News

AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study

AZN's baxdrostat hit the main goal in the phase III Bax24 study, showing significant blood pressure reductions in patients with resistant hypertension.

4 hours ago - Nasdaq

AstraZeneca (AZN) Reports Success in Phase 3 Hypertension Trial

AstraZeneca (AZN) Reports Success in Phase 3 Hypertension Trial

1 day ago - GuruFocus

AZN: Baxdrostat Shows Promising Results in Phase III Trial

AZN: Baxdrostat Shows Promising Results in Phase III Trial

1 day ago - GuruFocus

Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in a...

1 day ago - Business Wire

AZN : Baxdrostat Meets Primary Endpoint In Phase III Trial For Treatment-Resistant Hypertension

(RTTNews) - AstraZeneca (AZN, AZN.L,ZEG.DE,AZN.ST) announced that baxdrostat met the primary endpoint in the Bax24 Phase III trial, demonstrating a statistically significant and clinically meaningful ...

1 day ago - Nasdaq

AstraZeneca's Baxdrostat meets main goal in high blood pressure study

AstraZeneca said on Tuesday its drug Baxdrostat met the main goal in a late-stage study in patients with treatment-resistant high blood pressure, or hypertension.

1 day ago - Reuters

AstraZeneca (AZN) Signs $555 Million AI Agreement with Algen to Develop Therapies

AstraZeneca (AZN) Signs $555 Million AI Agreement with Algen to Develop Therapies

1 day ago - GuruFocus

AstraZeneca (AZN) Achieves Key Milestones in Breast Cancer Treatment Study

AstraZeneca (AZN) Achieves Key Milestones in Breast Cancer Treatment Study

2 days ago - GuruFocus

AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases

Algen Biotechnologies , a privately held biotech company specializing in advanced CRISPR gene modulation and AI-driven drug discovery, has announced a multi-target partnership with AstraZeneca Plc (NA...

2 days ago - Benzinga

AstraZeneca, Daiichi Sankyo succeed in late-stage breast cancer study

AstraZeneca & Daiichi Sankyo's Datroway shows improved survival in late-stage triple-negative breast cancer trial. Read more here.

2 days ago - Seeking Alpha

My Top 5 Biotech Stocks Big Pharma Could Buy Next

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...

2 days ago - Seeking Alpha

AstraZeneca signs up to $555 million deal with US-based Algen to develop gene therapies

Algen Biotechnologies said on Monday it has agreed to grant AstraZeneca a license to develop gene therapies the U.S.-based biotech discovers using its artificial intelligence-driven platform, in a dea...

2 days ago - Reuters

Algen Biotechnologies Announces Multi-Target Partnership to Advance AI-Powered Drug Discovery in Immunology with AstraZeneca

SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Algen Biotechnologies Announces Multi-Target Partnership to Advance AI-Powered Drug Discovery in Immunology with AstraZeneca.

2 days ago - Business Wire

DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02

DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom immuno...

2 days ago - Benzinga

AstraZeneca Reaches Analyst Target Price

In recent trading, shares of AstraZeneca plc (Symbol: AZN) have crossed above the average analyst 12-month target price of $85.09, changing hands for $85.31/share. When a stock reaches the target an a...

2 days ago - Nasdaq

AZN: Promising Phase 3 Trial Results for Breast Cancer Treatment

AZN: Promising Phase 3 Trial Results for Breast Cancer Treatment

2 days ago - GuruFocus

AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports

AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday.

2 days ago - Reuters

AstraZeneca's Datroway boosts survival in advanced breast cancer trial

AstraZeneca said on Monday its precision drug Datroway improved overall survival and progression free survival in patients with an advanced form of breast cancer versus chemotherapy in a trial when gi...

2 days ago - Reuters

Astrazeneca (AZN) Rises Higher Than Market: Key Facts

Astrazeneca (AZN) closed at $85.31 in the latest trading session, marking a +1.98% move from the prior day.

4 days ago - Nasdaq

Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated

Drug stocks are poised to outperform in 2025, driven by conservative valuations and a research renaissance in key therapeutic areas. US healthcare spending growth and transformative GLP-1 therapies, e...

4 days ago - Seeking Alpha

AstraZeneca Stock Is Up 10% on Tariff News. But Is the Pharmaceutical Giant a Buy?

The uncertainty about U.S. pharmaceutical tariffs shouldn't be as worrisome for AstraZeneca now.

6 days ago - The Motley Fool

AstraZeneca (AZN) Urged to Consider U.S. Headquarters

AstraZeneca (AZN) Urged to Consider U.S. Headquarters

6 days ago - GuruFocus

AstraZeneca Shares Leap 4.2% on Breakthrough Cancer Drug Approval and Robust Q3 Outlook

The Anglo-Swedish pharmaceutical giant, AstraZeneca PLC, has set off a stock market spurt in itself, soaring 4.2 per cent. to a five-month high after both announcing regulatory green lights on a next-...

6 days ago - ABC Money

FTSE 100 hits another high despite concerns over US government shutdown

Drug companies AstraZeneca, Hikma Pharmaceuticals and GSK were all big risers.

7 days ago - Evening Standard